Trial · NCT06898515
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hierarchical composite/win-ratio | 1. up to 30 days from randomization, 2. up to 30 days from discharge, 3. up to 72 hours after randomization | 1. Freedom from 30-day CV mortality 2. Freedom from HF Rehospitalization 30 days post-discharge 3. Greater net sodium loss per 24 hours during treatment |
| Primary | Incidence of device/procedure-related adverse events (KDIGO stage 2 or greater AKI, CAUTI) | initiation of randomized therapy through 72 hours following completion of randomized therapy | KDIGO stage 2 or greater AKI: ≥ doubling of serum creatinine or use of renal replacement therapy; CAUTI per CDC definition |
| Secondary | Net sodium loss | per 24 hours at end of randomized therapy | |
| Secondary | Time to discharge readiness | through hospital discharge, an average of 5 days | Time from initiation of randomized therapy to when the participant becomes medically ready for discharge from a decompensated heart failure treatment standpoint |
| Secondary | Time on IV diuretic therapy | randomization through hospital discharge, assessed up to 30 days | |
| Secondary | Net fluid loss | per 24 hours at end of randomized therapy | Fluid input subtracted from total urine output |
| Secondary | Weight loss | per 24 hours at end of randomized therapy | |
| Secondary | CV mortality and cumulative HF rehospitalizations | 90 days after hospital discharge | Both types of events will be combined in a total "event rate" compared between groups |
| Secondary | Length of stay | through hospital discharge, an average of 5 days | Time from initiation of randomized therapy to hospital discharge |
| Secondary | Hypotension defined as systolic blood pressure < 80 mmHg documented with two readings at least 30 minutes apart with symptoms (e.g., chest pain, dizziness) or <80 mmHg requiring an intervention including IV fluids or vasopressors. | initiation of randomized therapy up to 12 hours after stopping randomized therapy | |
| Secondary | Severe electrolyte abnormality | initiation of randomized therapy up to 72 hours after stopping randomized therapy | serum potassium \<3.0 mEq/L with ≥ 0.5 mEq/L decrease from initiation of randomized therapy, magnesium \<1.3 mEq/L with ≥0.5 mEq/L decrease from initiation of randomized therapy, or sodium \<125 mEq/L with ≥ 5.0 mEq/L decrease from initiation of randomized therapy |
| Secondary | Worsening heart failure requiring a higher level of HF therapy | initiation of randomized therapy up to 72 hours after stopping randomized therapy | |
| Secondary | Tinnitus or hearing loss lasting more than 30 minutes | initiation of randomized therapy up to 12 hours after stopping randomized therapy |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06898515/registered